Month: July 2024

Unleashing the Inner Leader with Prime Performance Strategies

Unleashing the Inner Leader with Prime Performance Strategies
Now taking applications for the Masterful Women Leaders Program

For high-achieving women who are ready to take their leadership to the next level, Prime Performance Strategies has the ideal coaching and mastermind program, and applications are now officially open.

Introducing Masterful Women Leaders, a transformational leadership coaching program that is designed to empower ambitious women to help them hone their skills, amplify their voices, and achieve their full leadership potential.

Learn from Debora Trimpe, a Doctor of Philosophy in Psychology with a specialization in Industrial and Organizational Psychology and the proud founder of Prime Performance Strategies. With her over 40 years of experience working in the areas of adult learning, talent development, and coaching, she is passionate about helping women become the best future leaders possible.

The Masterful Women Leaders program offers expert instruction, interactive workshops, a supportive network, and personalized coaching. This is perfect for women who have had a few years of leadership experience under their belt and are looking to improve their skills to obtain different results. Further, this program will equip women with the tools and strategies to master effective communications, build strong relationships, break down barriers, and advance one’s career goals.

Connect with a powerful community of like-minded women with Prime Performance Strategies. Join the Masterful Women Leaders program and send Dr. Debora an email at Debora@primeperformancestrategies.com to know more.

About Prime Performance Strategies

Prime Performance Strategies is dedicated to truly assessing and developing strategies that meet the challenges of their clients.

Media Contact
Company Name: Prime Performance Strategies
Contact Person: Debora Trimpe
Email: Send Email
Country: United States
Website: https://primeperformancestrategies.com/

Pancreatic Ductal Adenocarcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research. Learn more about our innovative pipeline today! @ Pancreatic Ductal Adenocarcinoma Pipeline Outlook

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

  • June 2024:- AstraZeneca- A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors.  This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
  • June 2024:- Genentech Inc.- A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma. The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
  • DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
  • The leading Pancreatic Ductal Adenocarcinoma Companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
  • Promising Pancreatic Ductal Adenocarcinoma Therapies such as Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.

Stay informed about the cutting-edge advancements in Pancreatic Ductal Adenocarcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

  • Onvansertib: Cardiff Oncology

Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

  • Nadunolimab: Cantargia

Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

  • Zimberelimab: Arcus Biosciences

Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

Learn more about Pancreatic Ductal Adenocarcinoma Drugs opportunities in our groundbreaking A Pancreatic Ductal Adenocarcinoma Research and development projects @ Pancreatic Ductal Adenocarcinoma Unmet Needs

Pancreatic Ductal Adenocarcinoma Companies

Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Pancreatic Ductal Adenocarcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology disease @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

  • Coverage- Global
  • Pancreatic Ductal Adenocarcinoma Companies- Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
  • Pancreatic Ductal Adenocarcinoma Therapies- Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.
  • Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Pancreatic Ductal Adenocarcinoma Pipeline on our website @ Pancreatic Ductal Adenocarcinoma Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pancreatic Ductal Adenocarcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NIS 793: XOMA
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CEND 1: Cend Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. DCC-3116: Deciphera Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. RMC-6236: REVOLUTION Medicines
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Ductal Adenocarcinoma Key Companies
  21. Pancreatic Ductal Adenocarcinoma Key Products
  22. Pancreatic Ductal Adenocarcinoma- Unmet Needs
  23. Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
  24. Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
  25. Pancreatic Ductal Adenocarcinoma Analyst Views
  26. Pancreatic Ductal Adenocarcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Ductal Adenocarcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Exosomes Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight, “Eczema Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Eczema Research. Learn more about our innovative pipeline today! @ Eczema Pipeline Outlook

Key Takeaways from the Eczema Pipeline Report

  • June 2024:- LEO Pharma- A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 mg/g in Chinese Adults and Adolescents (12-17 Years of Age) With Moderate to Severe Chronic Hand Eczema. The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema (CHE).
  • June 2024:- AnaptysBio Inc.- A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis. This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD). This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
  • DelveInsight’s Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
  • The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Eczema Therapies such as Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.

Stay informed about the cutting-edge advancements in Eczema Treatments. Download for updates and be a part of the revolution in dermatology care @ Eczema Clinical Trials Assessment

Eczema Emerging Drugs Profile 

  • Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. 

  • BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis. 

  • LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

Learn more about Eczema Drugs opportunities in our groundbreaking Eczema Research and development projects @ Eczema Unmet Needs

Eczema Companies

Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. 

Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Eczema Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Eczema Treatment by visiting our website. Stay informed about how we’re transforming the future of dermatology disease @ Eczema Market Drivers and Barriers, and Future Perspectives

Scope of the Eczema Pipeline Report

  • Coverage- Global
  • Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Eczema Therapies-Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Eczema Pipeline on our website @ Eczema Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Eczema: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Eczema– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Amlitelimab: Kymab
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Eczema Key Companies
  21. Eczema Key Products
  22. Eczema- Unmet Needs
  23. Eczema- Market Drivers and Barriers
  24. Eczema- Future Perspectives and Conclusion
  25. Eczema Analyst Views
  26. Eczema Key Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosomes Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Future Of Automotive Industry Size worth 104 million units by 2030

“Future Of Automotive Industry”
Future of Automotive Industry, Covers Original Equipment Manufacturer (OEM) Landscape, Connected Vehicles, Autonomous Driving Technologies, Electric Vehicles (Evs), Innovations In Battery Technology, Powertrains And Shared Mobility – Global Forecast 2030

The automotive industry, encompassing PV, LCV, and MHCV, size is projected to grow from 88 million units in 2024 and is projected to hit 104 million units by 2030, at a CAGR of 2.4%.

The growth of the automotive industry is influenced by various factors such as adoption of electric vehicles, development and manufacturing of long-range batteries along with installation of fast and ultra-fast charging points, introduction of autonomous vehicles, deployment of 5G connectivity and trends related to shared mobility.

Countries such as China, Brazil, South Korea and India have increased their investments in the development of automotive industry due to the growing urban population and economy in these countries. Due to such investment demand for automotive market will be more during the forecast period.

Autonomous vehicles are anticipated to witness significant growth

The introduction of autonomous cars with enhanced safety features and higher level of automation is shifting the trends in the automotive market. Numerous OEMs are introducing Level 2 (L2) and Level 3 (L3) autonomous vehicles, including Nissan (Japan), Honda (Japan) , Audi (Germany), BMW (Germany), and Mercedes-Benz (Germany). OEMs such as BMW and Mercedes have received approval for L3 autonomous vehicles in Germany and the US, respectively. BMW has also received approval to test its L3 vehicles in Shanghai, China. We expect L3 vehicle sales to gain pace in 2024 as these OEMs start rolling out their L3 models. In addition to testing the cars on roads several tech giants and OEMs have adopted acquisition strategies to take over smaller companies that operate in the space of developing driverless or autonomous technology. The number of Level 3 (L3) autonomous vehicles is projected to grow at a CAGR of 86.5% between 2023 and 2030. The Level 4 (L4) autonomous vehicle market is expected to experience limited commercial growth, primarily in select markets.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142125279

Growing adoption of connected vehicles

The total addressable market (TAM) for connected vehicle technologies is forecasted to surge from USD 0.8 billion in 2023 to USD 568 billion by 2035. This growth is driven by enhanced features and services, with potential earnings of USD 1,600 per car annually. Connectivity in vehicles provides better consumer experience, efficient data-driven services and opens innovative business models. Future cars will offer over 300 connected features, signaling the automotive industry’s shift towards more connected, autonomous, shared, and electric vehicles, driving a fundamental transformation in mobility. In 2022, approximately 90% of the connected cars had integration of 4G technology. However, with 5G connectivity the share of connected cars is expected to grow. It is expected that over 20% of the cars on road will be connected to cellular network by the end of 2024. Companies have started exploring the connectivity space to gain first mover advantage in the market. For instance, in December 2023, Magna, a major supplier in the automotive industry joined Telia and Ericsson’s NorthStar Program to innovate and deploy the 5G ADAS system.

“Asia Pacific is expected to be the largest market during the forecast period”

Asia-Pacific region hold the major share in the sales volume of PV and CV combined. The major factor for this is the intensive manufacturing and export of cars in China. The Chinese market is the worlds largest market in terms of vehicle sales as well as production. In 2023, China’s sales volume for passenger vehicles was over 25 million units, with a share of around 50% globally. China is the most dominant nation in automotive industry with respect to supplying raw materials, manufacturing as well as its sales. China has the most powerful supply chain of EV batteries. Over 50% of the EV batteries are manufactured in China. Moreover, around 75% of the components of EV batteries are manufactured in China. These Chinese manufacturers are looking to expand their services and acquire additional market share around the world. The Asia region has seen growth in automobile production in 2022 and 2023. Continuing this trend, the Asia region will dominate the market during the forecast period.

Key Players

The top automobile OEMs in the market are Toyota Motors Corporation (Japan), Tesla (USA), Volkswagen AG (Germany), Ford (USA) , BYD (China), Hyundai Motor Corporation (South Korea) and so on. The other companies that support the automobile industry with technology development are ABB, Siemens, Nvidia, Waymo, Bosch and others. These companies adopted new product launches, acquisitions, partnerships, collaborations, and other key strategies to gain traction in the automotive market.

Request Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=142125279

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/future-of-automotive-industry-142125279.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Future Of Automotive Industry Size worth 104 million units by 2030

SPOT Drone Imaging Services, LLC Enhances Operational Efficiency Across Industries with Advanced Drone Technology

SPOT Drone Imaging Services, LLC, a leader in drone imaging technology, proudly announces the continuation and expansion of its services throughout the Southeast USA. Established in 2016 by COL David E. Cowley, USA (Ret.), Owner/Chief Pilot, alongside Kathleen D. Cowley, Vice President, SPOT Drone Imaging Services caters to diverse sectors including construction, industrial inspection, agriculture, and commercial real estate, providing cutting-edge solutions such as Drone Flight Training.

State-of-the-Art Drone Services for Multiple Industries

SPOT Drone Imaging Services offers a comprehensive range of applications, including Aerial Photos & Videos, Aerial Inspections, Real Estate Photography, Construction Support, Farm Scanning, SceneScape 360 (Aerial & Ground Virtual Tours), and professional Drone Flight Training. Their expertise covers Construction Progress Imaging, Precision Agriculture, RTK (Real-Time Kinematic) Drone Services, and extensive inspections for cell towers, facades, roofs, as well as solar and wind farms. Renowned for their advanced “Blue Drones” used in infrastructure inspection, SPOT Drone ensures precise data acquisition and analysis, enhancing decision-making and operational efficiency.

Commitment to Excellence and Community Engagement

As a service-disabled veteran-owned small business, SPOT Drone Imaging Services is dedicated to excellence in drone operations and actively contributes to its community. David Cowley, a key figure in the company, participates in the Denver-Lake Norman, NC Rotary Club. Additionally, the company sponsors local Little League Baseball teams, strengthening community ties and supporting local youth activities.

About SPOT Drone Imaging Services, LLC

Founded in 2017 and based in Denver, NC, SPOT Drone Imaging Services, LLC provides comprehensive drone imaging solutions for the construction, industrial inspection, agriculture, and commercial real estate sectors, along with professional drone training. As a leader in the drone services industry, SPOT Drone is committed to delivering reliable, timely, and high-quality drone data to support clients in achieving their operational goals.

For more information on how SPOT Drone Imaging Services can assist your business, please visit SPOT Drone Imaging Services.

Media Contact
Company Name: SPOT Drone Imaging Services
Contact Person: David Cowley
Email: Send Email
Phone: (704) 748-3895
Country: United States
Website: https://www.spotdroneimaging.com/

New Perspective Media Services, LLC Launches Advanced Aerial Imaging Services in Central Texas

New Perspective Media Services, LLC, a provider of aerial imaging solutions, officially announces the launch of its operations in Central Texas. Founded in 2024 by Raymond Hurley, the enterprise offers aerial photography and a comprehensive array of services tailored for the real estate, construction, insurance, and inspection industries.

Innovative Aerial Solutions for Diverse Needs

Raymond Hurley, Owner and CEO, and Pamela Yarborough, Managing Director, lead the venture, offering cutting-edge aerial photos and videos, aerial inspections, real estate photography, construction support, farm scanning, hotel and resort imaging, and the groundbreaking SceneScape 360. Their company aims to transcend traditional imaging by providing innovative aerial perspectives that enhance visualization and analysis for clients.

Aerial Excellence with a Focus on Quality and Innovation

New Perspective Media Services stands out for its commitment to unparalleled visual excellence and comprehensive services. Clients in diverse sectors can expect high-definition real estate imaging, dynamic SceneScape 360 presentations, and engaging content for advertising and events. The company’s mission is to capture the world from above, ensuring every aerial photograph or video surpasses expectations.

Future Expansion and Technological Advancements

Looking ahead, New Perspective Media Services plans to expand its offerings to include 3D mapping, thermal imaging for inspections, and valuable support for search and rescue operations. These initiatives aim to incorporate more detailed and functional imagery for a wide range of practical applications, enhancing service delivery across sectors.

Exceptional Service and Cutting-Edge Technology

With a clear focus on safety, compliance, and creativity, New Perspective Media offers a superior customer experience. They are not just flying drones; they are crafting a unique visual narrative for each client, using the sky as their canvas. The company ensures that all operations adhere to the highest standards of safety and professionalism, promising a secure and satisfactory experience for all clients.

For more information on New Perspective Media Services, LLC, and to explore their innovative aerial imaging services, visit New Perspective Media.

About New Perspective Media Services, LLC

Founded in 2024 and based in Temple, Texas, New Perspective Media Services, LLC specializes in aerial photography and videography. The company is dedicated to providing high-quality, reliable, and innovative aerial imaging solutions across Central Texas, supporting industries such as real estate, construction, insurance, and inspection with superior imagery and detailed insights.

Media Contact
Company Name: New Perspective Media
Contact Person: Raymond Hurley
Email: Send Email
Phone: (254) 970-2020
Country: United States
Website: https://newperspective.media

RAP Drone Services Becomes Preferred Provider for Keller Williams Realty Offices in Portland

RAP Drone Services, a leading provider of aerial photography and videography services, has announced its new partnership with Keller Williams Portland Central and Keller Williams Portland Elite as their preferred real estate photography provider. This partnership marks a significant milestone for RAP, emphasizing its commitment to providing high-quality visual solutions that enhance real estate marketing.

Founded in 2019 by Ken and Debbie Piper, RAP Drone Services has quickly established itself as a frontrunner in aerial real estate photography and construction site management through the use of advanced drone technology. “We aim to revolutionize how properties are presented in the market. Our collaboration with Keller Williams will allow us to reach and assist more real estate professionals and property owners than ever before,” said Ken Piper, Co-founder and CEO.

The company offers a variety of services including Aerial Photos & Videos, Aerial Real Estate Photography, Aerial Construction Support, and SceneScape 360, providing full panoramas that showcase properties with unparalleled clarity.

RAP Drone Services prides itself not only on its technological prowess but also on its deep-rooted mission to “elevate real estate marketing by crafting captivating photography and videography.” Each project is infused with the passion for delivering excellence that Ken and Debbie Piper promise to all their clients.

Client testimonials reflect the company’s impact and efficiency. Kayla H., a local business owner, shared, “Ken did a fantastic job of capturing our family’s pumpkin patch. Very professional to work with, and the engagement on social media like Instagram has been fantastic!” Another client, Alishia G., noted, “The turnaround for receiving my photos and videos was prompt, and the prices were competitive.”

In honor of Ken and Debbie’s late son Ryan Andrew Piper, the company was rebranded from Pipers Photography to RAP Drone Services. This touching tribute underpins the company’s values of family and perseverance. “It’s a name that holds our hearts – a testament to Ryan and our continued commitment to this community,” Debbie Piper remarked.

Looking to the future, RAP Drone Services aims to expand its influence in the real estate market, ensuring that every agent and homeowner experiences the benefits of professional drone photography.

About RAP Drone Services:

Located in Tualatin, Oregon, RAP Drone Services specializes in aerial photography and videography for the real estate and construction sectors. Their mission is to deliver exceptional quality through state-of-the-art technology and personalized services, making them the partner of choice for realtors and construction firms alike.

For more information about RAP Drone Services, please visit https://rapdroneservices.com or contact  (503) 782-8230.

Media Contact
Company Name: RAP Drone Services
Contact Person: Kenneth Piper
Email: Send Email
Phone: (503) 782-8230
Country: United States
Website: https://rapdroneservices.com

Visual Drone Productions LLC Introduces Aerial Photography Solutions to Enhance Real Estate Marketing in the Southeast

Visual Drone Productions LLC, a provider of aerial imaging services, is proud to announce the launch of its comprehensive suite of aerial photography solutions tailored to enhance the real estate sector. Established in 2023 by Roy Dudzic, the company is set to expand its bespoke services to multiple industries, helping clients gain a competitive edge, accelerate sales, and enhance profitability.

In the dynamic world of real estate marketing, where standing out is key to success, Visual Drone Productions offers a comprehensive suite of services, including Aerial Real Estate Photography, SceneScape 360 (Aerial & Ground Virtual Tours), Aerial Inspections, and detailed interior still photography. The company’s mission is to assist its clients in building a robust client base by significantly enhancing both the speed and profitability of real estate sales. Their services ensure properties are showcased in the best possible light, making listings hard to overlook.

Operating across the Southeast, Visual Drone Productions employs cutting-edge drone technology coupled with professional expertise to deliver high-quality, captivating video and photo content. These visual assets capture every nuance of a property, from sweeping aerial views to detailed interiors, providing prospective buyers with an immersive experience that traditional photography often fails to deliver.

The company’s aerial capabilities, combined with traditional real estate photography, enable them to offer an all-encompassing visual package that real estate agents can leverage. By presenting properties uniquely and engagingly, clients can differentiate themselves in a crowded market.

Looking forward, Visual Drone Productions plans to broaden its impact beyond real estate, eyeing opportunities in areas such as construction support and hospitality, particularly for hotels and resorts. Each new venture is underpinned by the company’s commitment to enhancing client visibility and improving sales outcomes, which are paramount in its operational ethos.

For more information about Visual Drone Productions LLC, its diverse range of services, to book a consultation, or to collaborate on a project, please visit Visual Drone Productions.

About Visual Drone Productions LLC

Visual Drone Productions LLC specializes in aerial photography and videography services using advanced drone technology. Founded by Roy Dudzic, the company is dedicated to assisting clients across industries in increasing their sales efficacy and market presence. Based in Spartanburg, SC, Visual Drone Productions is poised for rapid expansion into diverse sectors, driving marketing innovation with high-quality, impactful visual content.

Media Contact
Company Name: Visual Drone Productions
Contact Person: Roy Dudzic
Email: Send Email
Phone: (864) 365-2505
Country: United States
Website: https://visualdroneproductions.com/

Metastatic Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2024” report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Metastatic Colorectal Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Colorectal Cancer Pipeline Outlook

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

  • July 2024:- AbbVie- A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer. Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer.
  • June 2024:- Mirati Therapeutics Inc.- A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1. This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.
  • DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
  • The leading Metastatic Colorectal Cancer Companies such as Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Promising Metastatic Colorectal Cancer Pipeline Therapies such as ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.

Stay informed about the cutting-edge advancements in Metastatic Colorectal Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ Metastatic Colorectal Cancer Clinical Trials Assessment

Metastatic Colorectal Cancer Emerging Drugs Profile

  • Adagrasib (MRTX849): Mirati Therapeutics

Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRASG12C mutation. Adagrasib is being explored as a monotherapy as well as in combination with other anticancer drugs. The goal is to optimize efficacy and prevent treatment resistance, ensuring these potentially promising combination therapies can help patients throughout the course of their treatment journey. Extensive preclinical studies showed that combining adagrasib with a broad range of therapies, including PD-1, SHP2, Pan-EGFR, CDK 4/6, and SOS1 inhibitors, resulted in even more robust anti-tumor activity.

  • QL-1203: Qilu Pharmaceutical

QL-1203, is an investigational drug being developed by Qilu Pharmaceutical. QL-1203, acts as an epidermal growth factor receptor modulator. It belongs to the class of monoclonal antibodies. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Metastatic colorectal cancer.

  • ZN-c3: Zentalis Pharmaceuticals

ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with Metastatic Colorectal Cancer. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer.

Learn more about Metastatic Colorectal Cancer Drugs opportunities in our groundbreaking Metastatic Colorectal Cancer Research and development projects @ Metastatic Colorectal Cancer Unmet Needs

Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Metastatic Colorectal Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology disease @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Metastatic Colorectal Cancer Companies

Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.

Scope of the Metastatic Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Colorectal Cancer Pipeline on our website @ Metastatic Colorectal Cancer Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Metastatic colorectal cancer: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Metastatic colorectal cancer – DelveInsight’s Analytical Perspective

7. In-depth Commercial Assessment

8. Metastatic colorectal cancer Collaboration Deals

9. Late Stage Products (Phase III)

10. MRTX849: Mirati Therapeutics

11. Drug profiles in the detailed report…..

12. Mid Stage Products (Phase II)

13. AK-112: Akeso Biopharma

14. Drug profiles in the detailed report…..

15. Early Stage Products (Phase I)

16. SY 5609: Syros Pharmaceuticals

17. Drug profiles in the detailed report…..

18. Preclinical and Discovery Stage Products

19. Drug name: Company name

20. Drug profiles in the detailed report…..

21. Inactive Products

22. Metastatic colorectal cancer Key Companies

23. Metastatic colorectal cancer Key Products

24. Metastatic colorectal cancer- Unmet Needs

25. Metastatic colorectal cancer- Market Drivers and Barriers

26. Metastatic colorectal cancer- Future Perspectives and Conclusion

27. Metastatic colorectal cancer Analyst Views

28. Metastatic colorectal cancer Key Companies

29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DREA Exchange Leading the Cryptocurrency Market – Empowering Technology

In recent years, the development of the cryptocurrency market has been thriving. In this burgeoning industry, the DREA exchange, with its outstanding technical capabilities and innovative business strategies, is becoming a leader in the industry.

Since the beginning of 2023, the cryptocurrency market has gradually shown a trend of more stable price fluctuations. This is mainly due to the continuous emergence of financial derivative products such as spot Bitcoin ETFs, which have injected more liquidity and vitality into the entire market. Data shows that since the beginning of 2023, the volatility of Bitcoin prices has been maintained below 50%, which means that Bitcoin is gradually growing into a more mature and stable asset class.

As an industry leader, the DREA exchange has promptly grasped this market trend and provided users with an exceptional cryptocurrency trading experience. The exchange has won widespread recognition in the industry thanks to its outstanding security and advanced technological innovations.

The DREA exchange has an experienced team of cryptocurrency technology experts who are constantly optimizing the performance and stability of the trading system to ensure the security of user transactions and assets. At the same time, DREA exchange is developing more advanced quantitative trading robots and artificial intelligence analysis engines to enhance the trading experience and investment returns for users.

It is worth mentioning that in the past, many cryptocurrency investors often had to spend a lot of time and effort manually adjusting their investment portfolios. But with the digital asset management function of the DREA exchange, investors only need to set their own risk preferences, and the system can automatically adjust based on market changes, significantly improving investment efficiency. DREA exchange recently launched a brand new digital asset management function, providing users with a one-stop asset management solution.

In addition to technical capabilities, the DREA exchange is also keeping up in business expansion. The exchange is constantly expanding its global footprint, providing users with more convenient and efficient cross-border trading services. Currently, DREA exchange has set up operating centers in more than 10 countries and regions around the world, providing localized trading services for local users. At the same time, DREA exchange has also established good cooperation relationships with regulatory authorities in various regions to ensure its compliant business operations, further winning the trust of users.

Driven by both technological innovation and business expansion, the influence of the DREA exchange is constantly expanding. The exchange not only occupies an important position in the cryptocurrency spot trading field, but is also venturing into emerging fields such as digital asset derivatives trading and digital asset management, providing users with more comprehensive financial services.

In addition, DREA exchange will also increase its investment in social responsibility. The exchange will actively participate in public welfare and charity activities, and is committed to promoting the healthy development of the cryptocurrency industry. For example, DREA exchange will cooperate with local universities to carry out cryptocurrency-related education and training, helping more people understand and master the knowledge of this emerging field. At the same time, DREA exchange will continue to support relevant research on the cryptocurrency industry, and provide suggestions and opinions for the government to formulate regulatory policies.

With its innovative operating strategies and advanced technical capabilities, DREA exchange is becoming the leader in the cryptocurrency trading market. The exchange not only provides users with an exceptional trading experience, but also actively fulfills the social responsibility of industry development, which will inject new momentum into this constantly evolving market and promote the healthy and orderly development of the cryptocurrency industry.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: DREA Exchange
Email: Send Email
Address:7 Victoria Road
City: East Central
State: London
Country: United Kingdom
Website: https://www.drea.band